Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUVENAL E MARTINEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1558459529
CMS profile
69926
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,313.52

50 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,313.52 50

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUVENAL E MARTINEZ

NPI 1558459529 · CMS profile ID 69926

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558459529?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558459529?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558459529?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558459529?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

50 matching records · $1,313.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 50 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 50.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4912/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118057593 CMS
Lilly USA, LLC $11.4411/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135116277 CMS
Novo Nordisk Inc $20.3311/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097630116 CMS
Novo Nordisk Inc $0.3511/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097818685 CMS
IDORSIA PHARMACEUTICALS US INC $17.5010/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146792652 CMS
Exact Sciences Corporation $24.7010/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114774980 CMS
AstraZeneca Pharmaceuticals LP $17.7410/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104736669 CMS
Lilly USA, LLC $12.2210/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135088255 CMS
Lilly USA, LLC $14.1609/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135113430 CMS
Amgen Inc. $6.6409/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117320300 CMS
Lilly USA, LLC $11.1309/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135116275 CMS
Lilly USA, LLC $109.3109/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135075767 CMS
Smith+Nephew, Inc. $30.9009/04/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1149614982 CMS
AstraZeneca Pharmaceuticals LP $19.7008/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104595542 CMS
Novo Nordisk Inc $5.3808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096864165 CMS
Exact Sciences Corporation $24.7608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114774974 CMS
Lilly USA, LLC $13.2908/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135075765 CMS
Lilly USA, LLC $14.2607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135103757 CMS
Novo Nordisk Inc $21.3407/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097664631 CMS
Lilly USA, LLC $12.9006/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135088253 CMS
Amgen Inc. $6.6906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117320298 CMS
Novo Nordisk Inc $121.8705/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096857072 CMS
Exact Sciences Corporation $24.7605/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114774968 CMS
Azurity Pharmaceuticals, Inc. $23.9205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134009543 CMS
AstraZeneca Pharmaceuticals LP $19.6705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105855194 CMS
Novo Nordisk Inc $20.0005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096572424 CMS
AstraZeneca Pharmaceuticals LP $7.3605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104581668 CMS
Lilly USA, LLC $14.2705/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135113428 CMS
AstraZeneca Pharmaceuticals LP $16.6104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105878397 CMS
Novo Nordisk Inc $1.4804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096983168 CMS
Novo Nordisk Inc $1.4804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097696166 CMS
Novo Nordisk Inc $1.5704/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096743513 CMS
Lilly USA, LLC $124.9904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135091941 CMS
Lilly USA, LLC $13.9704/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135093525 CMS
Novo Nordisk Inc $4.6804/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097087953 CMS
Novo Nordisk Inc $18.9103/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097744182 CMS
Lilly USA, LLC $11.0403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135075763 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.8503/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118057591 CMS
Exact Sciences Corporation $22.8203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114774964 CMS
Novo Nordisk Inc $23.9703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097016975 CMS
PFIZER INC. $15.3402/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132033333 CMS
AstraZeneca Pharmaceuticals LP $124.7802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104371387 CMS
Lilly USA, LLC $14.0902/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135075761 CMS
Amgen Inc. $6.4502/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111645153 CMS
Novo Nordisk Inc $21.3402/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096947488 CMS
Amgen Inc. $124.9902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111645155 CMS
AstraZeneca Pharmaceuticals LP $33.9702/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104390155 CMS
AstraZeneca Pharmaceuticals LP $22.2701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104471082 CMS
Lilly USA, LLC $14.0201/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135116273 CMS
Exact Sciences Corporation $22.8201/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114774958 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,824.81 72
PY2020 $1,108.16 66
PY2021 $1,714.64 78
PY2022 $1,279.40 50
PY2023 $1,687.36 46
PY2024 $1,313.52 50
PY2025 $665.19 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,400.63 16
PY2025 Principal investigator $701,734.65 46
PY2024 Principal investigator $1,015,383.57 140
PY2023 Principal investigator $1,037,707.93 416
PY2022 Principal investigator $88,070.01 24
PY2021 Principal investigator $334,298.45 64
PY2020 Principal investigator $148,277.65 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $21,124.00 12/22/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,272.86 12/19/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513284
Principal investigator 1 SANOFI US SERVICES INC. $4,515.00 11/17/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087356
Principal investigator 1 GlaxoSmithKline, LLC. $7,000.00 11/12/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192099389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,705.34 10/29/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513288
Principal investigator 1 GlaxoSmithKline, LLC. $2,125.00 10/29/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099394
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 10/29/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099401
Principal investigator 1 SANOFI US SERVICES INC. $8,077.00 10/20/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087307
Principal investigator 1 SANOFI US SERVICES INC. $8,181.00 10/06/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087283
Recipient GlaxoSmithKline, LLC. $113.85 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192099374
Recipient GlaxoSmithKline, LLC. $34.91 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192099378
Recipient GlaxoSmithKline, LLC. $103.36 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192099407
Recipient GlaxoSmithKline, LLC. $237.63 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192149797
Recipient GlaxoSmithKline, LLC. $37.40 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192186531
Recipient GlaxoSmithKline, LLC. $119.99 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192186535
Recipient GlaxoSmithKline, LLC. $20.94 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192186544
Recipient GlaxoSmithKline, LLC. $527.02 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192186546
Principal investigator 1 SANOFI US SERVICES INC. $7,482.00 09/03/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087274
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,096.98 08/27/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513138
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 08/11/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087255
Principal investigator 1 UCB SA $13,322.88 07/31/2025 Non-covered Recipient Entity
Anchor Medical Research, Llc
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658748
Principal investigator 1 Alnylam Pharmaceuticals Inc. $29,881.56 07/16/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513142
Principal investigator 1 Alnylam Pharmaceuticals Inc. $60,757.00 07/16/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513170
Principal investigator 1 SANOFI US SERVICES INC. $7,501.00 07/14/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226087226
Recipient GlaxoSmithKline, LLC. $37.80 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099353
Recipient GlaxoSmithKline, LLC. $34.53 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099361
Recipient GlaxoSmithKline, LLC. $35.04 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099367
Recipient GlaxoSmithKline, LLC. $515.26 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192099384
Recipient GlaxoSmithKline, LLC. $75.86 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192149801
Recipient GlaxoSmithKline, LLC. $291.79 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192186522
Recipient GlaxoSmithKline, LLC. $87.59 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192186527
Recipient GlaxoSmithKline, LLC. $127.66 07/09/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192186539
Principal investigator 1 SANOFI US SERVICES INC. $18,905.00 06/27/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085208
Principal investigator 1 SANOFI US SERVICES INC. $15,665.00 05/29/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085200
Principal investigator 1 Alnylam Pharmaceuticals Inc. $32,361.21 05/21/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513059
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 05/07/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085196
Principal investigator 1 PFIZER INC. $1,800.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228722916
Principal investigator 1 PFIZER INC. $275.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228789970
Principal investigator 1 PFIZER INC. $15,990.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228791032
Principal investigator 1 PFIZER INC. $2,500.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228791845
Principal investigator 1 PFIZER INC. $500.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792032
Principal investigator 1 PFIZER INC. $500.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792237
Principal investigator 1 PFIZER INC. $450.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792266
Principal investigator 1 PFIZER INC. $1,500.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792368
Principal investigator 1 PFIZER INC. $1,200.00 04/23/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792588
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,855.75 04/18/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513080
Principal investigator 1 Alnylam Pharmaceuticals Inc. $362.37 04/09/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513076
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68,255.21 04/01/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513072
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,002.27 03/12/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215512970
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,706.55 03/12/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215512973
Principal investigator 1 SANOFI US SERVICES INC. $10,300.00 03/10/2025 Non-covered Recipient Entity
Anchor Medical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,180.43 02/03/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $83,604.98 02/03/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513026
Principal investigator 1 Amgen Inc. $92,292.28 01/30/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246639133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $230.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,279.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $613.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,717.00 01/24/2025 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215512962
Principal investigator 1 Amgen Inc. $91,847.98 01/22/2025 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639131